Healthcare Realty Reports Third Quarter 2026 Results and Further Increases Full Year 2026 Guidance

Healthcare Realty Trust raised its 2026 Normalized FFO guidance to $1.65–$1.67 per diluted share, a $0.02 increase at the midpoint from July guidance. It also raised Same Store Cash NOI growth guidance to 5.00%–5.25%, up 75bps at the low end and 25bps at the high end.

Analysis

The more useful signal is the upward revision to same-store cash NOI, not the modest increase to FFO: it suggests better property-level operating performance, but the release alone does not establish whether leasing, occupancy, rent steps, or lower costs drove it. For a medical-office REIT, durable leasing and rent growth would support cash-flow visibility; a cost-driven lift may be less repeatable. The FFO revision is comparatively small, so do not extrapolate it into a major earnings reset without checking the full release for share count, interest expense, dispositions, and the bridge from NOI to FFO.

Near term, the guidance raise is a mild positive catalyst, but the price response depends on valuation and how much improvement was already expected—neither is supplied. Over the next 1–3 months, track leasing spreads, occupancy, tenant retention, and whether management sustains or raises the revised outlook. Over 6–18 months, higher financing costs or healthcare-provider pressure could offset rent growth; conversely, sustained organic NOI growth would improve the quality of HR’s cash flows. The contrarian risk is treating one guidance revision as proof of a broad medical-office recovery. A reversal in same-store NOI guidance, weaker leasing/occupancy, or a material increase in funding costs would falsify the constructive read.

Key Decisions for Investors

• Treat the announcement as a modest positive, not a standalone reason to chase HR; assess the full earnings release and current valuation before sizing exposure.
• Watch the next disclosure for the drivers of the NOI revision—leasing and occupancy gains are more durable than temporary expense timing—and compare those metrics with healthcare REIT peers.
• If HR’s price reaction is muted and the report confirms broad-based organic growth without deterioration in financing costs, consider a measured relative-value long in HR versus a healthcare-REIT peer basket; avoid the trade if the NOI uplift is narrowly cost-driven.
• Falsification alert: reduce the constructive view if management reverses the revised NOI outlook, leasing or occupancy weakens, or financing costs rise enough to absorb property-level gains.